Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2809–2832 of 50,397 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer Clear all

Conditions: Advanced Melanoma, Stage III and IV Melanoma
Interventions: Biological: MKC1106-MT, Biological: MKCC1106-MT; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Los Angeles, California • Tampa, Florida

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation; Other · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 12
States / cities: Anchorage, Alaska • Bozeman, Montana • Kennewick, Washington + 7 more

Conditions: Metastatic Breast Cancer
Interventions: Taxotere, Cytoxan, Trastuzumab deruxtecan, Sacituzumab govitecan, Xeloda, Fulvestrant, Ribociclib, Abemaciclib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostatic Neoplasms, Prostate Cancer, Recurrence
Interventions: [18F]CTT1057, [68Ga]Ga-PSMA-11; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Lymphoma, B-cell Lymphoma
Interventions: Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion, IL-2, Carmustine, Etoposide, Cytarabine, Melphalan; Procedure · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Adenocarcinoma Non-resectable
Interventions: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation; Drug · Radiation
Lead sponsor: Scripps Health; Other
Eligibility: Up to 90 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Support Group Therapy, Symptom Management Service (SMS) Consultation, Quality of Life (QOL) Questionnaires, Interview; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Renal Cell Carcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Sarcoma, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab, Ziv-Aflibercept; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Bethesda, Maryland • Boston, Massachusetts

Conditions: Non-Hodgkin's Lymphoma
Interventions: intravenous T900607-sodium; Drug
Lead sponsor: Tularik; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 5
States / cities: La Jolla, California • Aurora, Colorado • Chicago, Illinois + 1 more

Conditions: Neuroblastoma
Interventions: buthionine sulfoximine, melphalan, Peripheral blood stem cell infusion, Filgrastim; Drug · Procedure · Other
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: Up to 30 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more

Conditions: Pancreatic Neoplasms, Metastases, Neoplasm
Interventions: GEMZAR, ALIMTA; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 40
States / cities: Huntsville, Alabama • Fountain Valley, California • Fullerton, California + 37 more

Conditions: Brain Tumor, Low Grade Glioma, Astrocytoma, Ependymoma, Ganglioglioma
Interventions: Proton radiotherapy; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 1 Year to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
Interventions: Ruxolitinib, Retifanlimab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide, Lenalidomide, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine Sulfate; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Atlanta, Georgia • City of Saint Peters, Missouri • Creve Coeur, Missouri + 11 more

Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Malignant Posterior Tongue Neoplasm, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage II Hypopharyngeal Carcinoma AJCC v8, Stage II Laryngeal Cancer AJCC v8, Stage II Nasopharyngeal Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma
Interventions: Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer, Constipation, Pain
Interventions: Naloxegol, Placebo; Drug
Lead sponsor: Hospice of Henderson County, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: New York, New York • Flat Rock, North Carolina • Cleveland, Ohio

Conditions: Neurofibromatosis Type 1, Tibial Dysplasia
Interventions: Not listed
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: Not listed
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lymphoma
Interventions: Biopsy, fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography, [3'-deoxy-3'-[F-18] fluorothymidine, computed tomography, fine-needle aspiration; Procedure · Diagnostic Test · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Basal Cell Carcinoma
Interventions: Video-Based Informed Consent; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Atlanta, Georgia • Decatur, Georgia

Conditions: Cancer
Interventions: Not listed
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2035
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mycosis Fungoides
Interventions: Mechlorethamine Hydrochloride Gel, Total Skin Electron Beam Radiation Therapy; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, AML (Acute Myeloid Leukemia)
Interventions: CD64 CAR T Cells; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Sarcoma
Interventions: bevacizumab, doxorubicin hydrochloride; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Salt Lake City, Utah

Conditions: Multiple Myeloma
Interventions: XL999; Drug
Lead sponsor: Symphony Evolution, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • Joliet, Illinois

Search by objective public record fields.

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Study of Diagnostic Performance of [18F]CTT1057 in BCR

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer

Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Study of T900607-Sodium in Previously Treated Patients With Non-Hodgkin's Lymphoma.

N99-02: Melphalan and Buthionine Sulfoximine

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation

Retifanlimab and Ruxolitinib In Solid Malignancies

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia

18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma

Video-Based Treatment Options for Basal Cell Carcinoma

Inherited CAncer REgistry

Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma

Study of XL999 in Patients With Multiple Myeloma